相关实验视频

Updated: Jun 26, 2025

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

泰利塔西对循环Gd-IgA1和IgA含有的免疫复合体在IgA脏病中的作用

Jincan Zan¹, Lijun Liu¹, Guisen Li²

¹Renal Division, Peking University First Hospital Peking University Institute of Nephrology Key Laboratory of Renal Disease, Ministry of Health of China Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education. Research Units of Diagnosis and Treatment of Immune-mediate Kidney Disease, Chinese Academy of Medical Sciences, Beijing, China.

Kidney international reports

|May 20, 2024

概括

在IgA脏病患者中,Telitacicept有效降低了银河糖缺乏IgA1和IgA免疫复合体. 这些减少与蛋白尿减少相关,这表明治疗反应的潜在生物标志物.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

免疫球蛋白A (IgA) 病 (IgAN) 是一种慢性病.
一种TACI融合蛋白Telitacicept通过向BAFF和APRIL,在治疗Igan方面表现出有效性.
目前,对IGAN中特利塔cept反应的预测生物标志物尚不清楚.

研究的目的:

为了确定血清生物标志物,预测IGAN患者对telitacicept的临床反应.
分析Gd-IgA1,IgA免疫综合体和补充因子之间的变化与蛋白尿减少之间的关联.

主要方法:

第二阶段临床试验,涉及24名IgAN参与者 (安慰剂,160毫克,240毫克特利塔西组).
在基线和4,12,24周收集的血样本.
测量了Gd-IgA1,IgA含有免疫复合体,C3a,C5a和sC5b-9.0的水平.

主要成果:

泰利塔西显著降低了Gd-IgA1,IgG-IgA和多IgA免疫复合体,以剂量依赖的方式.
减少Gd-IgA1和IgA免疫复合体与减少蛋白尿相关.
没有观察到C3a,C5a或sC5b-9水平的显著变化.

结论:

泰利塔西cept有效地减少了IgAN中的循环Gd-IgA1和IgA含有的免疫复合体.
免疫复合体IgA的水平与蛋白尿减少相关,作为潜在的生物标志物.
需要进一步的研究来验证这些生物标志物是否适用于个性化治疗策略.

关键词:

在Gd-IgA1A1中.的IgA免疫复合体.在IgA脏病发作中,IgA脏病发作捕鱼达克,这是一个很好的方法.生物标志物生物标志物泰利塔的接收方式

更多相关视频

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

相关概念视频

Transcytosis of IgG

Transcytosis of IgG

Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...